KyungdongPharm

At a glance

KyungdongPharm filed 40 disclosures in the last 12 months, including 10 insider, 4 5% holder, 3 buyback and 1 issuance. The most recent key filing was on Oct 30: A major holder's stake rose from 45.75% to 45.79% (open-market buy).

Revenue for 2025 was ₩196B, up 1.2% on 2024. Operating margin was 3.9% against 1.4% a year earlier. Debt was 41% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩100B and operating profit of ₩6.1B.

The 2025 annual report lists 363 employees with an average tenure of 10.2 years and average pay of ₩56M, #1169 of 1,829 listed companies by average pay. Its 8 directors and auditors were paid ₩191.3M each on average. It paid ₩300 per common share in cash dividends, against ₩300 a year earlier (+0%). 류기성 and related parties held 45.53% at year end.

Of 1 recent 5%+ holder report, 1 raised and 0 cut a stake; the largest stake reported was 45.79% on Oct 30.

From the 2025 annual report

Staff: 363 (185 men, 178 women), of whom 11 on fixed-term contracts. Total pay for the year: ₩20.3B. Directors and auditors: 8, paid ₩1.5B in total.

Dividends (common shares)

Largest shareholder

류기성 holds 17.51%; with 52 related parties the group holds 45.53% of common shares at year end (from 45.32% at the start of the year).

Individuals paid ₩500M or more

Auditor: 한영회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports